ArticleBMC infectious diseases2026
Co-occurrence of triple ESBL-associated genes (bla
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) among Gram-negative bacteria, particularly those producing extended-spectrum β-lactamase (ESBLs), represents a significant global healthcare challenge. CTX-M enzymes have achieved global dominance, often disseminated through plasmid-mediated horizontal gene transfer, complicating treatment in resource-limited settings. This study aimed to determine prevalence, antimicrobial resistance patterns and ESBL-associated gene profiles in clinical Gram-negative isolates.
methodsA hospital-based cross-sectional study was conducted at Mahakali Provincial Hospital from November 2024 to February 2026. Using a consecutive sampling technique, 1485 clinical specimens (including urine, pus, blood, wound swabs, throat swabs and tissues) were processed for bacterial culture, identification, antimicrobial susceptibility testing and ESBL detection following CLSI 2024 guidelines. ESBL-associated genes (bla
resultsOf 1485 specimens, 478 (32.3%) were culture-positive, yielding 411 (86.0%) Gram-negative bacteria. Urine samples accounted for 88.3% of isolates. E. coli (71.8%) and K. pneumoniae (15.6%) were the most common pathogens. Overall, 54.7% of isolates were multidrug-resistant (MDR). Among ESBL-screened Enterobacterales (n = 385), 108 (28.1%) were confirmed ESBL producers. Molecular analysis of 108 ESBL- producing MDR isolates revealed bla
conclusionsTo the best of our knowledge, this is the first report from Far-Western Nepal documenting the co-carriage of triple ESBL-associated genes in clinical Enterobacterales. These findings highlight a high regional burden of community-level resistance and emphasize the urgent need for continuous molecular surveillance, targeted antimicrobial stewardship and region-specific treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.